-
Protracted Venous Infusion of 5-Fluorouracil as a Chemotherapy in Colorectal Cancer
-
Hyun Sik Jeong, Won Seog Kim, Sook In Jung, Jong Tae Lee, Ki Hyun Kim, Sung Soo Yoon, Won Ki Kang, Hong Ghi Lee, Ken Chil Park, Poong Lyul Rhee, Hae Jun Kim, Ho Kyun Chun, Chan Hyung Park
-
J Korean Cancer Assoc. 1999;31(1):120-125.
-
-
-
 Abstract
 PDF
- PURPOSE
The administration of 5-fluorouracil (5-FU) by protracted intravenous infusion is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancers. This study was performed to evaluate the response rate and toxicities of protracted infusion of 5-FU in patients with advanced or recurrent colorectal cancers who had been treated with 5-FU by bolus or shortterm continuous administration.
MATERIALS AND METHODS
Between March 1995 and June 1997, twenty-eight patients with advanced colorectal cancer previously exposed to 5-FU based chemotherapy were enrolled in this triaL Patients received 5-FU (250 mg/m(2)/day days 1-28) or 5-FU plus leucovorin (5-FU; 200 mg/m/day days 1-28, leucovorin; 20 mg/m IV days 1, 8, 15, 21) by ambulatory infusion pump. Treatment course was repeated every 42 days until disease progression.
RESULT
Twenty-eight patients entered. All 28 patients were assessable for response and toxicity. Five (19%) patients achieved a partial response, with the median response duration of 15 weeks (range; 7-22 weeks), and median survival time of entire patients was 54 weeks (range 7-151+ weeks). Gastrointestinal toxicity, specifically stomatitis was a major toxicity (grade 2, 12%; grade 3, 4%), but hand-foot syndrome was less frequent (5%) compared with other trials with protracted infusion of 5-FU reported in the literature. Hematologic toxicity was generally of low grade.
CONCLUSION
Prolonged intravenous infusion of 5-FU can produce a response rate of 19% with low toxicity among patients refractory to bolus or short-term infusion of S-FU.
|
KCA
